Gelatin


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IV As a plasma vol expander in hypovolaemic shock As succinylated gelatin 4% w/v in water for inj: Vol and rate of infusion depend on the condition of the patient. Topical As a haemostatic As a sterile compressed sponge: Cut sponge to desired size and apply directly w/ pressure onto the bleeding site, either dry or saturated w/ sterile NaCl soln. Sponge may be left on the bleeding site, if needed. May be used w/ or w/o thrombin to obtain haemostasis.
Dosage Details
Intravenous
Plasma volume expander in hypovolaemic shock
Adult: As succinylated gelatin 4% w/v in water for inj: Volume and rate of infusion depend on the condition of the patient. Dose may be given rapidly (500 ml in 5-10 min) in severe acute blood loss until signs of hypovolaemia are relieved.

Topical/Cutaneous
Haemostatic
Adult: As a sterile compressed sponge: Cut sponge to desired size and apply directly with pressure onto the bleeding site, either dry or saturated with sterile NaCl solution. Sponge may be left on the bleeding site, if needed. May be used with or without thrombin to obtain haemostasis.
Contraindications
Topical: Not to be used in closure of skin incisions. Not to be placed in intravascular compartments. IV: Lactate-containing solutions are contraindicated in patients with liver impairment. Avoid use in patients with severe heart failure, bleeding disorders or renal failure.
Special Precautions
Topical: Sterile sponge cannot be resterilised; unused, opened envelopes of sponge should be discarded. Once haemostasis is achieved, excess sponge should be removed. Usage is not recommended in the presence of infection. Avoid packing or wadding sponge. Not to be used for controlling postpartum bleeding or menorrhagia. Not recommended for primary treatment of coagulation disorders. Not recommended to saturate sponge with antibiotic solution or dust with antibiotic powder. IV: May cause severe anaphylactic reactions. Caution when used in patients at risk of developing circulatory overload, pulmonary oedema or heart failure. Caution in renal impairment, haemorrhage or chronic liver disease. Monitor central venous pressure during the initial phase of infusion to detect fluid overload. Stop infusion immediately if patient develops signs of anaphylactic reactions or if there are signs of oliguria or renal failure. Monitor patient so that haematocrit does not fall <30% and observe for early signs of bleeding complications.
Adverse Reactions
Topical: Increased risk of infection, granuloma formation, fibrosis, compression of surrounding tissue due to fluid absorption. IV: Hypersensitivity reactions. Rapid infusion may stimulate release of histamine and other vasoactive substances.
Potentially Fatal: IV: Severe anaphylactic reactions.
Drug Interactions
May cause acute hypotension when used with ACE inhibitors.
Action
Description: Gelatin is a protein that is used as a haemostatic in surgical procedures. It works as a haemostatic by providing a physical meshwork within which clotting may occur. It is also used as a plasma volume expander in hypovolaemic shock. Gelatin rods may also be used to temporarily block tear outflow in the diagnosis of dry eye.
Pharmacokinetics:
Excretion: Succinylated gelatin: Half-life is about 4 hr; large percentage of the administered dose is removed renally within 24 hr.
Storage
Intravenous:
Do not store above 25°C. Do not freeze or refrigerate.
Topical/Cutaneous:
Store sterile compressed sponge at 25°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Gelatin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Gelfoam
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in